BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
Rhea-AI Summary
BioNxt Solutions (OTCQB: BNXTF) has closed the previously announced extension of its unsecured convertible debentures. The company amended debentures with principal amounts of $425,000, $285,000, $1,400,000, $865,000, $1,600,000 and $900,000, bearing 8% annual interest, to extend their maturities by one year.
The new maturity dates range from November 12, 2027 to March 14, 2028. As consideration, BioNxt issued 16,900,000 common share purchase warrants, each exercisable at $0.50 per share until August 21, 2027. Warrants and any shares issued upon exercise or conversion are subject to a four-month-plus-one-day hold period.
Positive
- Convertible debenture maturities extended by one year to dates between November 12, 2027 and March 14, 2028
- Issued 16,900,000 warrants exercisable at $0.50 per share until August 21, 2027
- Debentures continue to bear a disclosed interest rate of 8% per annum under amended terms
Negative
- Issuance of 16,900,000 new share purchase warrants creates potential future equity dilution for existing shareholders
- Extended maturities mean outstanding convertible debenture principal remains on the balance sheet for an additional one year
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, BC / ACCESS Newswire / August 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) is pleased to announce that it has closed its previously announced extension of unsecured convertible debentures (the "Debentures"), as initially disclosed in its news releases dated June 10 and 23, 2026.
The Company amended the terms of the Debentures in the principal amounts of
As consideration for the agreement of the Debenture holders to extend the maturity dates, the Company issued 16,900,000 common share purchase warrants of the Company (the "Warrants") to the beneficial holders of the Debentures. Each Warrant entitles the holder thereof to purchase one (1) common share of the Company (a "Share") at an exercise price of
The Warrants and any Shares issued upon exercise of the Warrants and the conversion of the Debentures are subject to a statutory hold period of four (4) months plus one (1) day from the date of issuance, in accordance with applicable securities legislation.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide. BioNxt is listed on the Canadian Securities Exchange: BNXT, OTCQB Markets: BNXTF and trades in Germany under WKN: A3D1K3.
For more Company information, please visit https://bionxt.com/ or review its profiles on www.sedarplus.ca and on the Canadian Securities Exchange's website, www.thecse.com.
BioNxt Solutions Inc.
Hugh Rogers, CEO and Director
Email: info@bionxt.com
Phone: +1 604-250-6162
Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire